Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial (Q45217739)

From Wikidata

Jump to navigation Jump to search

scientific article published in January 2004

Language	Label	Description	Also known as
English	Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial	scientific article published in January 2004

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

phase II clinical trial

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Ramesh K Ramanathan

1

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Jimmy J Hwang

2

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

William C Zamboni

3

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Frank A Sinicrope

4

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Howard Safran

5

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Michael K Wong

6

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Martin Earle

7

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Adam Brufsky

8

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Terry Evans

9

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Monica Troetschel

10

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Christine Walko

11

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Roger Day

12

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Helen X Chen

13

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Sydney Finkelstein

14

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

publication date

1 January 2004

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Cancer Investigation

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

858-865

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200039645

21 January 2018

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200039645

21 January 2018

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200039645

21 January 2018

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200039645

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200039645

21 January 2018

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200039645

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200039645

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200039645

21 January 2018

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200039645

21 January 2018

Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200039645

21 January 2018

Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200039645

21 January 2018

Identifiers

10.1081/CNV-200039645

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

release_u25kitahfbh7rgufdv37vhqtzy

1 reference

https://api.fatcat.wiki/v0/release/u25kitahfbh7rgufdv37vhqtzy

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45217739&oldid=2070398341"